|Bid||166,500.00 x 0|
|Ask||168,500.00 x 0|
|Day's range||153,500.00 - 167,000.00|
|52-week range||151,500.00 - 398,000.00|
|Beta (5Y monthly)||1.22|
|PE ratio (TTM)||N/A|
|Earnings date||28 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||2,000.00 (1.22%)|
|Ex-dividend date||29 Dec 2021|
|1y target est||249,857.00|
YONGIN, South Korea, May 02, 2022--GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2022.
YONGIN, South Korea & VANCOUVER, Canada, April 28, 2022--GC Biopharma (006280.KS) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, today announced that they have entered into a Development and Option agreement for Acuitas’ LNP technology.
YONGIN, South Korea, April 17, 2022--GC Biopharma (006280.KS), a South Korean biopharmaceutical company, takes part in a campaign to celebrate World Hemophilia Day.